See more : Northcliff Resources Ltd. (NCF.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Samebest Co., LTD. (8489.TWO) Income Statement Analysis – Financial Results
- Crimson Tide plc (TIDE.L) Income Statement Analysis – Financial Results
- BCLS Acquisition Corp. (BLSA) Income Statement Analysis – Financial Results
- PVV Infra Limited (PVVINFRA.BO) Income Statement Analysis – Financial Results
- CENAQ Energy Corp. (CENQU) Income Statement Analysis – Financial Results
Cardiovascular Systems, Inc. (CSII)
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.22M | 258.97M | 236.55M | 248.02M | 217.04M | 204.91M | 178.18M | 181.54M | 136.61M | 103.90M | 82.49M | 78.78M | 64.83M | 56.46M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Cost of Revenue | 63.44M | 61.13M | 48.76M | 47.68M | 39.48M | 39.44M | 35.42M | 39.52M | 31.04M | 24.38M | 19.22M | 16.28M | 15.00M | 16.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.78M | 197.84M | 187.79M | 200.34M | 177.56M | 165.47M | 142.76M | 142.02M | 105.57M | 79.52M | 63.27M | 62.50M | 49.83M | 40.27M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Gross Profit Ratio | 73.14% | 76.39% | 79.39% | 80.78% | 81.81% | 80.75% | 80.12% | 78.23% | 77.28% | 76.53% | 76.71% | 79.34% | 76.86% | 71.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 36.72M | 41.06M | 43.36M | 33.46M | 26.76M | 22.91M | 25.93M | 30.98M | 21.07M | 15.22M | 11.37M | 8.94M | 10.28M | 14.68M | 43.31M | 38.30M | 29.18M | 16.28M | 0.00 | 2.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 170.53M | 167.50M | 169.97M | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 66.37M | 62.37M | 62.45M | 59.82M | 13.02M | 12.19M | 5.33M | 2.99M | 0.00 | 1.28M |
| Other Expenses | 1.34M | 1.22M | 1.23M | 760.00K | -390.00K | -164.00K | 53.00K | -162.00K | -706.00K | -671.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.59M | 209.78M | 214.56M | 201.16M | 175.33M | 167.01M | 188.48M | 174.66M | 139.06M | 101.93M | 77.74M | 71.31M | 72.73M | 74.50M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Cost & Expenses | 272.03M | 270.91M | 263.32M | 248.84M | 214.81M | 206.45M | 223.90M | 214.18M | 170.10M | 126.32M | 96.96M | 87.59M | 87.73M | 90.69M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Interest Income | 817.00K | 499.00K | 1.74M | 2.44M | 1.33M | 383.00K | 0.00 | 0.00 | 0.00 | -1.62M | 5.00K | 12.00K | 402.00K | 3.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.74M | 1.97M | 1.68M | 1.72M | 500.00K | 0.00 | 23.00K | 1.03M | 1.35M | 2.32M | 1.42M | 1.44M | 2.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.34M | 1.22M | 1.23M | 3.45M | 3.93M | 4.14M | 3.92M | 2.32M | 1.37M | 973.00K | 872.00K | 716.00K | 600.00K | 470.00K | 2.25M | 683.00K | 1.29M | 1.30M | 0.00 | 0.00 |
| EBITDA | -34.46M | -10.72M | -25.54M | -825.00K | 2.23M | -1.54M | -35.35M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.33M | -35.07M | -963.00K | -39.07M | -32.78M | -16.68M | 726.00K | -3.79M |
| EBITDA Ratio | -14.59% | -4.14% | -10.80% | -0.33% | 1.03% | -0.75% | -19.84% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -34.44% | -62.12% | -1.64% | -244.37% | -7,431.97% | -1,999.76% | 100.00% | 0.00% |
| Operating Income | -35.81M | -11.93M | -26.77M | -825.00K | -1.70M | -1.54M | -56.08M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.90M | -34.23M | 2.24M | -34.49M | -34.07M | -18.44M | 726.00K | -3.79M |
| Operating Income Ratio | -15.16% | -4.61% | -11.32% | -0.33% | -0.78% | -0.75% | -31.47% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -35.32% | -60.63% | 3.82% | -215.75% | -7,725.17% | -2,211.27% | 100.00% | 0.00% |
| Total Other Income/Expenses | -817.00K | -1.24M | -233.00K | 760.00K | 3.54M | -164.00K | 53.00K | -185.00K | -1.80M | -1.62M | -2.32M | 0.00 | 28.00K | 1.31M | 5.45M | 5.26M | 399.00K | -797.00K | 0.00 | 0.00 |
| Income Before Tax | -36.62M | -13.17M | -27.01M | -65.00K | 1.84M | -1.71M | -56.02M | -32.82M | -35.29M | -24.04M | -15.44M | 0.00 | -22.87M | -32.93M | 7.69M | -29.24M | -33.67M | -19.24M | 0.00 | 0.00 |
| Income Before Tax Ratio | -15.50% | -5.09% | -11.42% | -0.03% | 0.85% | -0.83% | -31.44% | -18.08% | -25.83% | -23.14% | -18.72% | 0.00% | -35.28% | -58.31% | 13.13% | -182.86% | -7,634.69% | -2,306.83% | 0.00% | 0.00% |
| Income Tax Expense | 310.00K | 252.00K | 231.00K | 190.00K | 132.00K | 86.00K | 6.39M | -2.30M | -333.00K | 344.00K | 479.00K | 1.60M | 1.01M | -25.12M | -5.45M | -5.25M | 0.00 | 797.00K | 13.95M | 3.76M |
| Net Income | -36.93M | -13.42M | -27.24M | -255.00K | 1.71M | -1.79M | -56.02M | -32.82M | -35.29M | -24.04M | -16.79M | -11.13M | -23.90M | -9.11M | 7.69M | -29.25M | -33.67M | -19.24M | -13.95M | -3.76M |
| Net Income Ratio | -15.63% | -5.18% | -11.51% | -0.10% | 0.79% | -0.87% | -31.44% | -18.08% | -25.83% | -23.14% | -20.35% | -14.12% | -36.87% | -16.14% | 13.13% | -182.94% | -7,634.69% | -2,306.83% | -1,921.49% | 0.00% |
| EPS | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.90 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.80 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| Weighted Avg Shares Out | 39.23M | 38.83M | 34.28M | 33.54M | 33.15M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.67M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
| Weighted Avg Shares Out (Dil) | 39.23M | 38.83M | 34.28M | 33.54M | 33.61M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.77M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices
Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results
Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results
Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference
Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference
Cardiovascular Systems, OrbusNeich Scores FDA Approval For Scoreflex Scoring Balloon
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon
Source: https://incomestatements.info
Category: Stock Reports